Aptose Biosciences (APTOF) Company Report

Aptose Biosciences Inc. has rescheduled its special meeting of shareholders to a later date in January 2026, originally planned for January 16, 2026.
The postponement is due to pending final clearance from the SEC regarding the proxy statement.
The meeting is to approve the acquisition of Aptose by HS North America Ltd., a wholly owned subsidiary of Hanmi Pharmaceutical Co. Ltd., and a continuance under Alberta law.
The record date of December 12, 2025, for the meeting remains unchanged.
The company's board of directors unanimously recommends shareholders vote FOR the proposed resolutions.

Dec 19, 2025, 10:16 PM

Aptose Biosciences Presents Positive Tuspetinib Triple Therapy Data at ASH Meeting

APTOF

New Projects/Investments

Product Launch

Aptose Biosciences Inc. showcased updated clinical data for its tuspetinib (TUS) triple drug therapy (TUS+VEN+AZA) at the 2025 ASH Annual Meeting, highlighting high rates of efficacy and MRD-negative remissions in newly diagnosed AML patients.
The therapy achieved a 100% response rate (CR/CRh) at the 80 mg and 120 mg TUS dose levels, demonstrating activity across various AML populations, including those with adverse mutations.
Tuspetinib-based therapies maintained a strong safety profile, reporting no dose-limiting toxicities across all evaluable TUS dose levels.
Early results from the new 160 mg dose level show promising signs of blast clearance and MRD-negativity.

Dec 8, 2025, 12:15 PM

Aptose Biosciences Inc. Enters into Arrangement Agreement with Hanmi Pharmaceutical Co. Ltd. and HS North America Ltd.

APTOF

M&A

Takeover Bid

Delisting/Listing Issues

Aptose Biosciences Inc. entered into an Arrangement Agreement with HS North America Ltd. and Hanmi Pharmaceutical Co. Ltd. on November 18, 2025.
Under the agreement, outstanding shares, options, restricted share units (RSUs), and warrants of Aptose Biosciences Inc. will be exchanged for cash consideration, leading to their cancellation.
Registered shareholders have dissent rights, allowing them to receive the fair value for their shares from the Purchaser.
The company's Employee Stock Purchase Plan (ESPP) will be suspended, and participants will receive accumulated funds.

Nov 25, 2025, 2:43 AM

Aptose Biosciences Announces Acquisition by Hanmi Pharmaceutical

APTOF

M&A

Takeover Bid

Delisting/Listing Issues

Aptose Biosciences Inc. has entered into a definitive arrangement agreement for its acquisition by Hanmi Pharmaceutical Co. Ltd., with Hanmi Purchaser acquiring all outstanding common shares not currently owned by Hanmi.
Aptose minority shareholders will receive C$2.41 in cash per Common Share, which represents a 28% premium over Aptose's 30-day volume-weighted average price (VWAP) of C$1.88 on the Toronto Stock Exchange (TSX).
Hanmi currently owns 19.93% of Aptose's outstanding common shares and has provided over US$30 million in debt facilities to Aptose.
The transaction is subject to customary closing conditions, including court approval and approval from Aptose shareholders at a special meeting to be held no later than January 16, 2026.
Upon completion, Aptose expects to no longer be subject to Canadian securities legislation reporting requirements, and its common shares will be delisted from all stock exchanges, including the TSX.

Nov 19, 2025, 11:02 AM

Aptose Biosciences Reports Q3 2025 Results and Positive Tuspetinib Clinical Data

APTOF

Earnings

New Projects/Investments

Guidance Update

Aptose Biosciences Inc. reported a net loss of $5.1 million for the third quarter ended September 30, 2025, a decrease from $7.0 million for the comparable period in 2024.
As of September 30, 2025, the company's cash, cash equivalents, and restricted cash equivalents totaled $1.6 million. Aptose stated it does not have sufficient cash to fund operations and is relying on advances from Hanmi, while actively pursuing financing and cost reduction efforts to extend its cash runway.
In the TUSCANY clinical trial, tuspetinib in combination with VEN+AZA demonstrated 100% CR/CRh responses in 6 out of 6 patients treated at the higher 80 mg and 120 mg dose levels, surpassing the 66% rate expected from VEN+AZA alone. This led to a dose escalation to 160 mg.
Aptose will present updated clinical data for tuspetinib at the 67th American Society of Hematology (ASH) Annual Meeting scheduled for December 6-9, 2025.

Nov 13, 2025, 10:00 PM

Aptose Biosciences announces positive data from TUSCANY trial for AML treatment

APTOF

Product Launch

New Projects/Investments

Aptose Biosciences Inc. announced positive data from its Phase 1/2 TUSCANY trial for tuspetinib (TUS) in combination with venetoclax and azacitidine (TUS+VEN+AZA) in newly diagnosed Acute Myeloid Leukemia (AML) patients.
The TUS+VEN+AZA triplet achieved CR/CRh responses in 6 out of 6 (100%) patients at higher dose levels (80 mg and 120 mg TUS), exceeding the 66% rate expected from VEN+AZA alone, with an overall 90% CR/CRh response rate across 10 patients.
The therapy demonstrated efficacy and MRD-negativity across diverse mutational subtypes, including 88% CR/CRh responses in FLT3 wildtype AML.
The TUS+VEN+AZA triplet was well tolerated, showing no dose-limiting toxicities or significant adverse events like prolonged myelosuppression or QTc prolongation.
Dosing with the 160 mg TUS dose level is currently ongoing.

Oct 16, 2025, 11:45 AM

Aptose Biosciences and Hanmi Pharmaceutical Extend Loan Agreement

APTOF

Debt Issuance

New Projects/Investments

Aptose Biosciences Inc. has entered into a US$11.9 million Amended Facility Agreement with Hanmi Pharmaceutical Co. Ltd. to continue the development of tuspetinib for Acute Myeloid Leukemia (AML).
This uncommitted loan facility will be administered through multiple advances until December 31, 2025, with individual advances not exceeding US$2,000,000 and an annual interest rate of 6% on unpaid principal.
Aptose also received the final US$1.4 million advance from the prior June 2025 Facility Agreement, bringing the total from that agreement to US$8.5 million.
The company highlighted positive early data from the TUSCANY triplet Phase 1/2 study, where 9 out of 10 patients responded to tuspetinib triplet therapy, achieving 100% complete remission (CR/CRh) in the 80mg and 120mg cohorts.
The loan agreement is considered a related-party transaction, for which Aptose is relying on a "financial hardship" exemption from certain Canadian securities law requirements.